Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - August 12, 2024) - Investorideas.com, a go-to investing platform covering biotech and medical technology issues a snapshot on recent news and developments for the treatment of solid cancer tumors, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.Read the full article at Investorideas.comhttps://www.investorideas.com/News/2024 ...

Bellberry Human Research Ethics Committee Granted Full Ethics Approval to the Pindara Private Hospital for a Safety, Feasibility, and Dose Finding Study of Aethlon's Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 AntibodiesSAN DIEGO, Aug. 12, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that, on August 6, 2024, the Bellberry Human Resea ...

SAN DIEGO, Aug. 6, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal first quarter ended June 30, 2024, at 4:15 p.m. ET on Wednesday, August 14, 2024.Management will host a conference call on Wednesday, August 14, 2024, at 4:30 p.m. ET to review financial results and recent corporate developments. Following managem ...

财务数据和关键指标变化 - 截至2024年3月31日,公司现金余额约为5.4百万美元,截至2024年6月25日,现金余额约为9.1百万美元 [30] - 2024财年合并经营费用约为12.6百万美元,较2023财年的12.5百万美元增加约16.4万美元,主要是由于薪酬及相关费用增加约76.3万美元,部分被管理费用减少约57.8万美元和专业费用减少约2.1万美元所抵消 [31][32][33][34][35][36] - 由于上述因素,公司2024财年净亏损增加至12.2百万美元,而2023财年为12.0百万美元 [37] 各条业务线数据和关键指标变化 - 公司正在继续研究和临床开发其Hemopurifier治疗性血液过滤系统,该系统旨在捕获和去除有害的外泌体和致命性病毒 [9][10] - Hemopurifier在肿瘤学和生命威胁性传染病领域有潜在应用 [10] - 公司还在研究在器官移植领域使用Hemopurifier,最初关注从恢复的肾脏中去除病毒和有害载荷的外泌体 [11] 各个市场数据和关键指标变化 - 公司正在澳大利亚和印度开展Hemopurifier在肿瘤患者中的安全性、可行性和剂量研究试验 [17][21][22] - 公司还在印度维持Hemopurifier作为治疗危及生命的病毒感染的立场,目前有两个参与试点医院 [27] 公司战略和发展方向及行业竞争 - 公司正专注于肿瘤学领域,但也在关注器官移植领域的应用,正在准备发表相关论文 [54] - 公司希望通过Hemopurifier去除肿瘤产生的外泌体,提高抗PD-1疗法的疗效 [19] - 公司正在寻求与器官采购机构或商业公司合作,而不是独自开展器官移植领域的工作 [54] 管理层对经营环境和未来前景的评论 - 公司已获得澳大利亚中央阿德莱德地方卫生网络伦理委员会的全面伦理批准,这是一个重要里程碑 [17][43][44] - 公司预计未来几个季度将有多个潜在的创值里程碑,包括向澳大利亚和印度的其他几家医院提交伦理委员会申请 [22] - 公司对即将开展的临床试验感到兴奋和乐观 [29] 其他重要信息 - 公司已获得FDA批准其内部制造设施 [15] - 公司正在关注H5N1禽流感病毒的情况,但尚未测试Hemopurifier对当前病毒株的捕获能力 [13][14] 问答环节重要的提问和回答 问题1 **Marla Marin 提问** 伦理委员会批准如何有助于公司在其他地点推进临床试验 [41] **Steven LaRosa 回答** 伦理委员会批准是一个重要里程碑,可以推动后续的监管和实施工作,为在其他医院开展试验奠定基础 [43][44] 问题2 **Unidentified Analyst 提问** 如果获得所有所需批准,预计何时能完成18例患者的入组,以及后续PMA研究的时间安排 [50] **Steven LaRosa 回答** 公司已进行了可行性评估,选择了有足够患者群体的高质量临床试验中心,预计入组进度会比较顺利,但具体时间难以预测 [52][53] 问题3 **Unidentified Analyst 提问** 除了肿瘤学,公司在器官移植领域的进展如何 [53] **James Frakes 回答** 公司已完成大部分相关论文的撰写,未来可能会寻求与器官采购机构或商业公司合作,而不是独自开展这一领域的工作 [54]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to __________ COMMISSION FILE NUMBER 001-37487 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) NEVADA 13-36328 ...

Exhibit 99.1 Aethlon Medical Announces Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Corporate Update Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, June 27, 2024 -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal year ended March 31, 2024 and provided an update on recent developments. Company Updates Aethlon Medic ...

Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, June 27, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal year ended March 31, 2024 and provided an update on recent developments. Company Updates Aethlon Medical is continuing the research and clinical development of its Hemopurifier®, a therapeutic blood filtration system ...

SAN DIEGO, June 21, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal year ended March 31, 2024, at 4:15 p.m. ET on Thursday, June 27, 2024. Management will host a conference call on Thursday, June 27, 2024, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal ...

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 20, 2024) - Investorideas.com, a goto investing platform, releases an industry snapshot looking at the future treatment of solid cancer tumors, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases. Read the full article on Investorideas.com https://www.investorideas.com/News/2024/biotech/06200Treatments-for-Cancer-Patients-wi ...

Aethlon Medical Granted Full Ethics Approval From the Human Research Ethics Committee at Central Adelaide Local Health Network for a Safety, Feasibility, and Dose Finding Study of its Hemopurifier® in Cancer Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies SAN DIEGO, June 18, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that, on June, 13, 2024, ...